Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Demerger of Oil and Gas Assets

18 Dec 2015 07:00

RNS Number : 5242J
Fastnet Equity PLC
18 December 2015
 

18 December 2015

 

Fastnet Equity plc

("Fastnet" or the "Company")

Demerger of Oil and Gas Assets

 

Highlights

· Transfer of the Company's existing oil and gas assets into a new company named Fastnet Hydrocarbons Limited ("Fastnet Hydrocarbons")

· Fastnet Hydrocarbons is held by a trust for the future benefit of shareholders of the Company (the "Hive out")

· Unsecured 4 year term loan granted for €660,000 to finance residual running costs of oil and gas assets

· Fastnet will no longer have any ongoing interest or further cost exposure in respect of oil and gas assets

 

Cathal Friel, Non-Executive Chairman, commented:

"Today's announcement positions Fastnet to focus exclusively on the Company's strategy of pursuing acquisition opportunities within the healthcare sector. 

"Ring-fencing the Company's existing oil and gas assets in a trust structure is designed to allow the search for a buyer of these oil and gas assets to continue.

"In the event that this search process is completed, the Company's existing shareholders would receive any value generated from the disposal of these assets."

 

Details of transaction

Fastnet Hydrocarbons has acquired from the Company, for an aggregate sum of £1, the entire issued share capital of two of Fastnet's subsidiaries being Fastnet Oil & Gas (Ireland) Limited ("FOGI") and Pathfinder Hydrocarbon Ventures Limited ("PHVL") which hold the Celtic Sea and Moroccan oil and gas assets and liabilities respectively. The shares in Fastnet Hydrocarbons have been transferred into a bare trust ("Trust") established for the benefit of shareholders on the register of the Company as at the close of business on 16 December 2015, pro rata to their shareholdings in Fastnet at that date. Cathal Friel has been appointed as director of Fastnet Hydrocarbons.

 

All investment of equity and debt in FOGI and PHVL was written down to nil in the audited accounts of Fastnet for the financial year ending 31 March 2015. All previous loans made by the Company to FOGI and PHVL have, to the extent not repaid out of cash reserves by FOGI or PHVL, been formally waived by Fastnet prior to the Hive Out, reflecting their impaired value.

 

Fastnet has made an unsecured 4 year term loan of an aggregate of €660,000 to FOGI and PHVL at an annual rate of interest of 4 per cent. above LIBOR in order that those entities are able to meet their respective obligations under the existing oil and gas licences and to facilitate an orderly winding down of FOGI and PHVL.

 

To the extent any future value is realised from Fastnet Hydrocarbons, FOGI and/or PHVL, the trustees of the Trust will arrange for any returns of capital or distributions made to it by Fastnet Hydrocarbons to be paid to beneficiaries of the Trust, being the current shareholders of Fastnet as described above. The terms of the loan require it to be settled in full, including all principal and accrued interest, immediately upon any change of control, disposal of business or all or substantially all of their assets or insolvency event of Fastnet Hydrocarbons (and each part of the loan made to FOGI and PHVL individually is immediately repaid on a change of control, disposal of the business or all or substantially all of their assets or insolvency event of FOGI and PHVL respectively). Fastnet Hydrocarbons, FOGI and PHVL all undertake not to pay any dividends or make any distributions to shareholders until the loan is repaid in full.

 

As a result of the Hive Out, Fastnet will no longer have any ongoing interest and will not have any further exposure to further costs that may be incurred in maintaining the licences within FOGI and PHVL.

 

Related Party Transaction

The acquisition of the shares in each of FOGI and PHVL by Fastnet Hydrocarbons constitutes a related party transaction under Rule 13 of the AIM Rules for Companies due to Cathal Friel's shareholding and role as director of both Fastnet and Fastnet Hydrocarbons. The independent directors consider, having consulted with the Company's Nominated Adviser, that the terms of the transaction are fair and reasonable in so far as the Company's shareholders are concerned.

 

For further information please contact:

Fastnet Equity plc

+353 (1) 644 0007

Cathal Friel, Non-Executive Chairman

Shore Capital

(Nomad & Joint Broker)

+44 (0) 20 7408 4090

Bidhi Bhoma, Edward Mansfield

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

John Frain, Anthony Farrell

Camarco

+44 (0) 20 3757 4980

Billy Clegg / Zoe Moulton

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGGCAPUPAUQR
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.